Alnylam Pharmaceuticals

Yahoo Finance • 20 days ago

Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.11%.  March E-mini S&P futures (ESH26) are down -0.11%, and March E-mini N... Full story

Yahoo Finance • last month

Catalyst Watch: Santa Claus Effect, M&A votes on Electronic Arts and TrueCar, index shuffling

[Futuristic display screen with a bar graph and colorful spreadsheet financial data] matejmo Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that... Full story

Yahoo Finance • last month

Alnylam’s Manufacturing Expansion and Extra-Hepatic RNAi Delivery Could Be A Game Changer For Alnylam Pharmaceuticals (ALNY)

In December 2025, Alnylam Pharmaceuticals announced a US$250 million expansion of its Norton, Massachusetts siRNA manufacturing facility and, together with PeptiDream, achieved a preclinical milestone showing macrocyclic peptide–siRNA conj... Full story

Yahoo Finance • last month

PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues

KAWASAKI, Japan, December 18, 2025--(BUSINESS WIRE)--PeptiDream Inc., a public Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), announced the achievement of a preclinical developmen... Full story

Yahoo Finance • last month

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipeline FDA has accepted Alnylam’s enzymatic ligation manufacturing platform into its Emerging Technolo... Full story

Yahoo Finance • last month

Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

MISSISSAUGA, ON, Dec. 16, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-... Full story

Yahoo Finance • last month

Assessing Alnylam Pharmaceuticals’ (ALNY) Valuation After Its Inclusion in the Nasdaq 100 Index

Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See our latest analysis for Alnylam Pharma... Full story

Yahoo Finance • last month

MicroStrategy retains place in key index despite delisting threats

Michael Saylor's Bitcoin (BTC) treasury company, Strategy (Nasdaq: MSTR), earlier known as MicroStrategy, has been successful in retaining its spot in the Nasdaq 100 (NDQ). A benchmark stock market index in the U.S., the Nasdaq 100 tracks... Full story

Yahoo Finance • last month

Lululemon Set to Exit Nasdaq 100 as Index Adds New Members

This article first appeared on GuruFocus. lululemon athletica inc. (LULU, Financials) is among the companies set to leave the Nasdaq 100 Index as part of the benchmark's annual reconstitution, according to an announcement released Friday.... Full story

Yahoo Finance • last month

200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party

This article first appeared on GuruFocus. Nasdaq officials have outlined a reshaping of the Nasdaq 100 that could redirect investor attention as the index approaches its annual reconstitution. Ahead of the market open on Dec. 22, Alnylam... Full story

Yahoo Finance • last month

Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions

[The NASDAQ Stock Exchange headquarters in New York, USA] JHVEPhoto Six companies, including Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) and Seagate Technology Holdings (STX [https://seekingalpha.com/symbol/STX])... Full story

Yahoo Finance • last month

Annual Changes to the Nasdaq-100 Index®

Nasdaq, Inc. NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December... Full story

Yahoo Finance • last month

$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players

Company Logo The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics MarketNon-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The "Non-Opioi... Full story

Yahoo Finance • last month

Is Alnylam Pharmaceuticals a Millionaire Maker?

Key Points Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising. Whether or not Alnylam is a millionaire maker, the stock should be able to generate exceptional long-term returns.10 sto... Full story

Yahoo Finance • last month

The S&P 500 Is Due to Rebalance on Friday. What Could Change.

The S&P 500 is set to undergo a quarterly rebalancing on Friday after the market closes. Alnylam Pharmaceuticals Ares Management CRH, and Vertiv Holdings are likely to join the benchmark index, according to KBW analyst Shreyank Gandhi, Bar... Full story

Yahoo Finance • 2 months ago

ALNY Quantitative Stock Analysis

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This mome... Full story

Yahoo Finance • 2 months ago

Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the equity markets continue... Full story

Yahoo Finance • 2 months ago

Hemophilia A Research Report 2025-2035: Market Driven by Innovation from Alnylam, Pfizer, Roche, Novo Nordisk, and Takeda as Next-Generation Therapies and Emerging Market Expansion Bolsters Growth

Company Logo Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors and gene therapy, are re... Full story

Yahoo Finance • 2 months ago

Hemophilia B Research Report 2025-2035: Market Led by UniQure, Pfizer, Novo Nordisk, HEMA Biologics, and Alnylam Pharmaceuticals as Next-Generation Therapies and R&D Investment Drive Innovation

Company Logo The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary treatments like Hemgenix and Beqv... Full story

Yahoo Finance • 2 months ago

Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy, stabiliz... Full story